"rationale","description","uuid:ID","id","label","name","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","e161f503-2876-45b7-9f7e-dc8987cac6b6","StudyDesign_1","","Study Design 1","StudyDesign"
